Table 3. Fold-change^* in genetic expression in bronchial epithelial cells and alveolar macrophages by treatment group.

		Sulforaphane Dose Group
Gene	N	Placebo	25 μmoles		150 μmoles		P-value†
		Median (Interquartile Range)
Alveolar macrophages
NQ01	81	0.80 (0.53–1.09)		1.03 (0.56–1.60)		0.94 (0.59–1.72)	0.45
HO1	81	0.90 (0.69–1.34)		0.98 (0.83–1.31)		1.06 (0.68–1.74)	0.40
AKR1C1	81	0.81 (0.46–1.27)		1.13 (0.38–1.99)		0.71 (0.56–1.57)	0.75
AKR1C3	81	1.03 (0.76–1.37)		1.02 (0.67–1.31)		0.87 (0.40–1.32)	0.49
Nrf2	81	1.14 (0.79–1.52)		1.05 (0.87–1.47)		1.13 (0.74–1.28)	0.88
Keap1	81	0.94 (0.66–1.17)		0.99 (0.82–1.11)		1.06 (0.59–1.32)	0.71
Bronchial epithelial cells
NQ01	82	1.09 (0.83–1.50)		1.12 (0.89–1.53)		0.96 (0.65–1.41)	0.69
HO1	84	1.05 (0.60–1.23)		1.12 (0.82–1.67)		0.93 (0.62–1.45)	0.53
AKR1C1	81	1.45 (0.84–1.98)		1.08 (0.85–2.14)		0.79 (0.53–1.08)	< .01
AKR1C3	81	1.10 (0.74–1.62)		1.38 (0.91–2.64)		0.87 (0.50–1.68)	0.06
Nrf2	83	1.09 (0.88–1.30)		1.06 (0.92–1.28)		1.06 (0.76–1.31)	0.68
PBMC
NQ01	85	0.88 (0.74–1.45)		1.17 (0.82–1.82)		1.29 (0.72–2.01)	0.31
HO1	86	1.09 (0.94.1.08)		0.92 (0.73–1.42)		1.10 (0.78–1.50)	0.10
AKR1C1	86	1.10 (0.49–1.98)		1.00 (0.49–1.76)		0.94 (0.71–2.39)	0.79
AKR1C3	87	1.03 (0071–1.30)		0.90 (0.68–1.45)		1.14 (0.80–2.07)	0.21
Nrf2	85	0.94 (0.74–1.08)		1.17 (0.82–1.82)		0.96 (0.76–1.28)	0.21

*Follow-up expression relative to baseline expression

†P-value based on Kruskal-Wallis test